- Home
- RPTX vs ADAG Comparison
RPTX vs ADAG Comparison
Compare RPTX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- ADAG
- Stock Information
- Founded
- RPTX 2016
- ADAG 2011
- Country
- RPTX Canada
- ADAG China
- Employees
- RPTX N/A
- ADAG N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- ADAG Health Care
- Exchange
- RPTX Nasdaq
- ADAG Nasdaq
- Market Cap
- RPTX 53.2M
- ADAG 81.9M
- IPO Year
- RPTX 2020
- ADAG 2021
- Fundamental
- Price
- RPTX $1.14
- ADAG $1.99
- Analyst Decision
- RPTX Strong Buy
- ADAG Strong Buy
- Analyst Count
- RPTX 3
- ADAG 1
- Target Price
- RPTX $4.50
- ADAG $8.00
- AVG Volume (30 Days)
- RPTX 166.6K
- ADAG 24.4K
- Earning Date
- RPTX 03-03-2025
- ADAG 03-17-2025
- Dividend Yield
- RPTX N/A
- ADAG N/A
- EPS Growth
- RPTX N/A
- ADAG N/A
- EPS
- RPTX N/A
- ADAG N/A
- Revenue
- RPTX $53,477,000.00
- ADAG $815,746.00
- Revenue This Year
- RPTX N/A
- ADAG N/A
- Revenue Next Year
- RPTX $7.11
- ADAG $2.70
- P/E Ratio
- RPTX N/A
- ADAG N/A
- Revenue Growth
- RPTX 4.58
- ADAG N/A
- 52 Week Low
- RPTX $1.06
- ADAG $1.64
- 52 Week High
- RPTX $6.03
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- RPTX 37.92
- ADAG 51.97
- Support Level
- RPTX $1.13
- ADAG $2.01
- Resistance Level
- RPTX $1.25
- ADAG $2.20
- Average True Range (ATR)
- RPTX 0.09
- ADAG 0.13
- MACD
- RPTX 0.00
- ADAG 0.01
- Stochastic Oscillator
- RPTX 22.86
- ADAG 24.32
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.